Physician profile
Yanglin Guo
NPI 1760893689
$10,176.63
in general payments reported to CMS, 2019-2025
36 companies · $1,910 in 2025
The $1,910 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,346 · 2020: $695 · 2021: $1,390 · 2022: $1,346 · 2023: $896 · 2024: $2,593 · 2025: $1,910.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,400 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,399.62 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,712.29 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Intuitive Surgical, INC. | $1,180.33 | 2023-2025 | Da Vinci Surgical System |
| Glaxosmithkline, LLC. | $983.68 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $969.99 | 2019-2025 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $808.70 | 2019-2025 | Ofev, Jascayd |
| Pfizer INC. | $617.84 | 2019-2025 | |
| Abbvie INC. | $408.19 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $365.46 | 2021-2025 | Dupixent |
| Pulmonx Corporation | $284.52 | 2020-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Merck Sharp & Dohme LLC | $278.22 | 2022-2025 | Zerbaxa, Winrevair, Recarbrio |
| Mallinckrodt Hospital Products INC. | $269.04 | 2020-2025 | Acthar |
| Inari Medical, INC. | $255.09 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $237.07 | 2019-2024 | |
| Genzyme Corporation | $211.25 | 2021-2025 | |
| United Therapeutics Corporation | $209.29 | 2019-2025 | Tyvaso, Tyvaso |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $142.23 | 2019 | |
| Astellas Pharma US INC | $138.02 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $135.00 | 2024 | Ultomiris |
| Ambu INC. | $126.33 | 2024-2025 | |
| Amgen INC. | $125.00 | 2022 | |
| Ani Pharmaceuticals, INC. | $94.74 | 2025 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $83.09 | 2019-2025 | Giapreza |
| Olympus America INC. | $77.31 | 2022-2025 | |
| Verona Pharma, INC. | $76.41 | 2025 | Ohtuvayre |
| Janssen Pharmaceuticals, INC | $70.04 | 2020-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $66.68 | 2023-2025 | Glassia |
| Circassia INC. | $46.32 | 2019-2020 | |
| Veran Medical Technologies, INC. | $36.12 | 2020 | |
| Vapotherm INC | $35.75 | 2020-2022 | |
| Gilead Sciences, INC. | $34.12 | 2019 | |
| Insmed, INC. | $26.26 | 2022-2024 | Arikayce |
| Novocure INC. | $17.50 | 2025 | Optune Lua (Novottf-200t) |
| Mylan Specialty L.P. | $14.61 | 2019 | |
| Avanos Medical | $14.14 | 2021 | |
| Genentech USA, INC. | $13.91 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanglin Guo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.